Plain-English translation of NCT04519619 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety study of Eylea (aflibercept), a medication injected into the eye to treat a serious condition called neovascular glaucoma, which happens when abnormal blood vessels grow in the eye and raise eye pressure dangerously. Researchers want to understand how well and how safely this medication works when used in everyday medical practice in Japan. You would be followed for six months to track how the treatment affects your eye health.
Neovascular glaucoma is a serious eye condition that can lead to vision loss if not treated properly. This study exists to gather real-world information about whether this medication is safe and works well for Japanese patients with this condition, beyond what was learned in earlier controlled research studies.
You likely qualify if…
You likely don't qualify if…
You would continue receiving your prescribed eye injections as planned with your doctor. During your treatment, you would visit the clinic at the start, at follow-up visits, and at the end (about six months total), where your doctor would collect information about how you're doing using a digital form. These would be your regular clinic visits — no extra tests or procedures beyond what your doctor already does for your eye care.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Japan